FMC FMC CORP
Chemicals & Allied Products · NYSE · SEC CIK 37785 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-22.0%
TTM net income YoY-696.3%
TTM EPS YoY-678.8%
Revenue 3-yr CAGR-17.2%
Net income 3-yr CAGR—
Margins
Gross margin22.0%
Operating margin-97.0%
Net margin-151.2%
FCF margin13.1%
EBITDA margin-91.0%
Returns
ROE-226.7%
ROA-42.6%
ROIC (approx.)-38.4%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets99.9%
Debt / equity—
Current ratio1.66x
Interest coverage-9.96x
Cash quality & payout
Operating cash flow / net income-0.10x
Accruals ratio-46.8%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.47B | $4.25B | $4.49B | $5.80B | $5.05B |
| Cost of revenue | $2.18B | $2.60B | $2.66B | $3.48B | $2.88B |
| Gross profit | $1.28B | $1.65B | $1.83B | $2.33B | $2.16B |
| R&D expense | $266.10M | $278.00M | $328.80M | $314.20M | $304.70M |
| SG&A expense | $684.90M | $644.60M | $734.30M | $775.20M | $714.10M |
| Operating income | -$1.63B | $506.50M | $555.60M | $1.14B | $1.03B |
| Interest expense | $239.60M | $235.80M | $237.20M | $151.80M | $131.10M |
| Pretax income | -$1.89B | $252.50M | $300.20M | $983.90M | $897.80M |
| Income tax | $314.20M | -$150.90M | -$1.12B | $145.20M | $92.50M |
| Net income | -$2.24B | $341.10M | $1.32B | $736.50M | $739.60M |
| EBITDA | -$1.45B | $682.80M | $739.90M | $1.31B | $1.21B |
| EPS (basic) | -17.88 | 2.73 | 10.55 | 5.83 | 5.76 |
| EPS (diluted) | -17.88 | 2.72 | 10.53 | 5.81 | 5.73 |
| Dividends declared per share | 1.82 | 2.32 | 2.32 | 2.17 | 1.96 |
| Weighted avg. shares (diluted) | 125.16M | 125.36M | 125.53M | 126.71M | 129.15M |
| Balance sheet | |||||
| Cash & equivalents | $584.50M | $357.30M | $302.40M | $572.00M | $516.80M |
| Receivables | $2.06B | $2.90B | $2.70B | $2.87B | $2.58B |
| Inventory | $1.22B | $1.20B | $1.72B | $1.65B | $1.52B |
| Current assets | $4.96B | $4.96B | $5.13B | $5.44B | $5.05B |
| PP&E, net | $707.40M | $849.70M | $892.50M | $849.60M | $817.00M |
| Goodwill | $0 | $1.51B | $1.59B | $1.59B | $1.46B |
| Intangibles | $2.36B | $2.36B | $2.47B | $2.51B | $2.52B |
| Total assets | $9.69B | $11.65B | $11.93B | $11.17B | $10.67B |
| Current liabilities | $3.76B | $3.02B | $3.38B | $3.80B | $3.52B |
| Short-term debt | $1.31B | $337.40M | $934.00M | $540.80M | $440.80M |
| Long-term debt | $2.77B | $3.03B | $3.02B | $2.73B | $2.73B |
| Total debt | $4.07B | $3.37B | $3.96B | $3.27B | $3.17B |
| Total liabilities | $7.59B | $7.14B | $7.49B | $7.77B | $7.53B |
| Shareholders' equity | $2.07B | $4.49B | $4.41B | $3.38B | $3.12B |
| Net debt | $3.49B | $3.01B | $3.66B | $2.70B | $2.66B |
| Cash flow statement | |||||
| Operating cash flow | -$6.20M | $736.70M | -$300.30M | $660.00M | $898.60M |
| Capital expenditure | $96.30M | $67.90M | $133.90M | $142.30M | $100.10M |
| Free cash flow | -$102.50M | $668.80M | -$434.20M | $517.70M | $798.50M |
| Investing cash flow | -$99.70M | $263.60M | -$154.40M | -$266.40M | -$131.70M |
| Financing cash flow | $386.00M | -$870.10M | $331.50M | -$237.40M | -$747.90M |
| Depreciation & amortization | $173.60M | $176.30M | $184.30M | $169.40M | $170.90M |
| Stock-based compensation | $24.00M | $23.80M | $25.90M | $24.20M | $17.80M |
| Dividends paid | $291.30M | $290.60M | $290.50M | $267.50M | $247.20M |
| Share buybacks | $0 | $0 | $75.00M | $100.00M | $400.00M |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.